Investigating the relationship between BRAF status and melanoma response to anti-angiogenic therapy
<p>A large phase 3 trial (AVAST-M) assessing bevacizumab as adjuvant therapy for melanoma has shown that patients with BRAF V600E melanomas had improved disease-free interval compared to the wild-type (WT) BRAF population, suggesting a differential sensitivity of BRAF V600E to Bevacizumab. Bev...
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | أطروحة |
| منشور في: |
2019
|